EGFR and non-small cell lung carcinoma: In a study of advanced NSCLC patients treated with gefitinib, Douillard et al reported an ORR of 76.9% and PFS of 10.2 months based on plasma‐detected EGFR mutants.10 The independent review committee assessed PFS to be 11 months for ctDNA EGFR mutant patients treated with gefitinib in the ENSURE study.13, 14 In our study, the ORR, DCR, and PFS for the treatment group were 90%, 100%, and 10 months, respectively.